MedTrace Logo

Pomalidomide in Treating Patients With Kaposi Sarcoma and Human Immunodeficiency Virus Infection

NCT03601806 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2026-04-13

Study results available
· View outcomes & findings →

Summary

This phase II clinical trial studies the side effects of pomalidomide and how well it works in treating patients with Kaposi sarcoma and human immunodeficiency virus (HIV) infection. Biological therapies, such as pomalidomide, may stimulate the immune system in different ways and stop tumor cells from growing and it may also block the growth of new blood vessels necessary for tumor growth.

Conditions

  • Human Immunodeficiency Virus 1 Positive
  • Skin Kaposi Sarcoma

Interventions

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Pomalidomide

Given PO

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • The Emmes Company, LLC

    collaborator INDUSTRY

  • University of Arkansas

    collaborator OTHER

  • Montefiore Medical Center

    collaborator OTHER

  • University of Stellenbosch

    collaborator OTHER

  • Weill Medical College of Cornell University

    collaborator OTHER

  • University of California, Los Angeles

    collaborator OTHER

  • AIDS Malignancy Consortium

    lead NETWORK

Principal Investigators

  • Susan E. Krown, MD · AIDS Malignancy Consortium

  • Samantha Vogt, MD, MPH · Johns Hopkins University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-26
Primary Completion
2024-11-29
Completion
2025-04-10
FDA Drug
Yes

Countries

  • Kenya
  • Malawi
  • Uganda

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03601806 on ClinicalTrials.gov